Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 0.52 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.39 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.38 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vinylsulfonic Acid SCHEMBL5912826 | 0.88 | DNM1 (0.59) | SLC22A1SLC22A2TP53ALDH1A1CYP3A4 | |
| Vinylsulfonic Acid SCHEMBL5912551 | 0.88 | DNM1 (0.59) | SLC22A1SLC22A2TP53ALDH1A1CYP3A4 | |
| Tetrabuthylammonium SCHEMBL795552 | 0.87 | SLC22A1 (0.52) | SLC22A1SLC22A2TP53ALDH1A1CYP3A4 | |
| Tetrabuthylammonium SCHEMBL27990806 | 0.84 | SLC22A1 (0.67) | SLC22A1SLC22A2TP53ALDH1A1CYP3A4 | |
| Tetrabuthylammonium SCHEMBL243899 | 0.84 | SLC22A1 (0.67) | SLC22A1SLC22A2TP53ALDH1A1CYP3A4 | |
| Vinylsulfonic Acid SCHEMBL5376241 | 0.82 | DNM1 (0.58) | TSHRSMN1; SMN2HSD17B10DNM1ENPP2 | |
| Cetrimonium SCHEMBL5380732 | 0.82 | DNM1 (0.58) | TSHRSMN1; SMN2HSD17B10DNM1ENPP2 | |
| Tetrabuthylammonium SCHEMBL9935686 | 0.82 | SLC22A1 (0.46) | SLC22A1SLC22A2TP53ALDH1A1CYP3A4 | |
| Tetrabuthylammonium SCHEMBL9998667 | 0.81 | SLC22A1 (0.63) | SLC22A1SLC22A2TP53ALDH1A1CYP3A4 | |
| Tetrabuthylammonium SCHEMBL331036 | 0.81 | SLC22A1 (0.63) | SLC22A1SLC22A2TP53ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10586995-B2 | Method for the fabrication of homogenous blends of polystyrenesulfonic acid and polyvinylidene fluoride suitable for the application in direct oxidation methanol fuel cells (DMFCs) | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2020-03-10 | — | — | US | disclosed |
| CN-102883602-B | Method for reducing virulence of bacteria | UWM研究基金会有限公司 | 2017-07-18 | — | — | CN | disclosed |
| US-20160049678-A1 | New Method for the Fabrication of Homogenous Blends of Polystyrenesulfonic Acid and Polyvinylidene Fluoride Suitable For The Application In Direct Oxidation Methanol Fuel Cells (DMFCs) | UNIVERSITY OF SOUTHERN CALIFORNIA | 2016-02-18 | — | — | US | disclosed |
| US-9260382-B2 | Methods of reducing virulence in bacteria | UWM RESEARCH FOUNDATION (US) | 2016-02-16 | — | — | US | disclosed |
| US-20130267571-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| EP-2616056-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | Neuroquest Inc. (CA) | 2013-07-24 | — | — | EP | disclosed |
| EP-2536275-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | UWM Research Foundation, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20120322769-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | DUKE UNIVERSITY (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2012034232-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011103189-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | UWM RESEARCH FOUNDATION, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322769-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | PGLS, RRS1, MRPL21 | SLC22A1 3445/4885SLC22A2 3854/4885TP53 3660/4885 |
| US-20130267571-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | PMP22, PTGES, GGPS1 | SLC22A1 868/4885SLC22A2 936/4885TP53 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.